Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q77632445)
Watch
English
Rational development of capecitabine
scientific article published on 01 February 2002
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
review article
1 reference
stated in
Europe PubMed Central
title
Rational development of capecitabine
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
main subject
capecitabine
1 reference
based on heuristic
inferred from title
author name string
M Venturini
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
publication date
1 February 2002
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
published in
European Journal of Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
volume
38 Suppl 2
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
page(s)
3-9
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
cites work
Clinical pharmacology of 5-fluorouracil
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous 5-fluorouracil in the treatment of breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous infusional chemotherapy for early breast cancer: the Royal Marsden Hospital experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fluoropyrimidines: a closer look at their toxicities
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fluoropyrimidines in the treatment of colorectal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A study of quality of life in cancer patients receiving palliative chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Patient preferences for oral versus intravenous palliative chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
What is the role of thymidine phosphorylase in tumor angiogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thymidine phosphorylase is angiogenic and promotes tumor growth.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Future treatment options with capecitabine in solid tumours
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical pharmacokinetics of capecitabine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improving the quality of reporting of randomized controlled trials. The CONSORT statement
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900414-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0959-8049(01)00414-2
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
PubMed ID
11841929
1 reference
stated in
Europe PubMed Central
PubMed ID
11841929
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11841929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit